The study consisted of a blinded, randomized clinical trial involving 46 dogs recruited from the public. The animals were randomly assigned to receive either the Oximunol supplement (0.5mg/kg body weight) or a placebo once daily over a period of six months. The Oximunol supplement’s potential benefit to canine wellness was assessed by analyzing owner responses to standardized questions regarding the health status of their pets, before and after the supplement period.
With these positive results and the absence of any negative effects upon the animals, Chemaphor is proceeding with additional clinical efficacy studies, financially supported by an NRC IRAP grant, that are designed to further define the Oximunol supplement’s animal wellness benefits.
At the same time, Chemaphor is moving forward in executing its commercialization plan for the launch of companion animal wellness products, including outsourcing the manufacture of canine oral supplements and carrying out work to have the Oximunol supplement meet global regulatory and animal health partner needs. Discussions are underway with potential marketing, sales and distribution partners to position Oximunol supplements as premium-value products targeted towards veterinary and ‘pet boutique’ sales channels.
Paul Dick, CEO of Chemaphor, said: “The successful outcome of the pilot trial, achieved with a low level of supplementation, is an exciting first milestone in our companion animal commercialization project announced in August 2009.
“The in vivo results in the dogs support in a very practical way the in vitro laboratory findings of the Oximunol supplement’s effects upon immune function, consistent with the Oximunol supplement ‘lending a helping hand’ in maintaining and enhancing animal health. This achievement provides major impetus to the launch of our first companion animal wellness product within a year.”